Calciferol (Dihydrotachysterol) is used in the therapeutic domain of systemic conditions and applies to conditions involving fluctuating manifestations, acute episodes, and systemic or localized discomfort. The medicine is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden.

---

Support for Episodic Symptom Discomfort

This medicine is considered relevant for easing symptoms related to heightened physiological activity and those associated with acute or episodic changes. It generally helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.

---

Assistance with Temporary Functional Strain

Calciferol (Dihydrotachysterol) is often used during phases when symptoms become more noticeable, particularly in conditions where functional stability becomes affected. It may assist with maintaining functional stability, offering symptomatic relief that helps patients cope more steadily.

---

Management of Disruptive Symptom Patterns

This agent is applicable within clinical settings that involve acute or disruptive symptom patterns, such as those that create noticeable physiological strain. It provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during symptomatic periods.

Quick Fact: Support for Symptoms that Create Noticeable Physiological Strain

---

Stabilization in Acute Clinical Scenarios

The medication is commonly used when short-term symptomatic assistance is needed, especially in conditions characterized by periods of heightened symptoms. It plays a role in managing symptoms of increased neurological or muscular activity, supporting general well-being during symptomatic phases.

Who Can and Cannot Use Calciferol (Dihydrotachysterol)?

The eligibility profile for Dihydrotachysterol is defined by strict regulatory rules focusing on a patient’s existing metabolic status and organ function.

Populations Prohibited from Use (Contraindicated) Dihydrotachysterol is strictly contraindicated in patients with existing hypercalcemia (high blood calcium levels) or hypervitaminosis D (excessive Vitamin D). It is also contraindicated in individuals with known hypersensitivity to the drug or an allergy to nuts (peanuts). For safety, one regulatory authority specifies the medicine is contraindicated in breastfeeding mothers.

Populations Requiring Conditional Use Use is conditional for several groups due to the risk of hypercalcemia. Patients with impaired renal function must be treated with extreme caution and require mandatory, intensive follow-up of kidney function and calcium levels. Patients with sarcoidosis or certain pre-existing conditions like heart disease or a history of renal stones should only use the medicine under specific, monitored circumstances. Pre-existing hyperphosphatemia must be corrected before treatment begins.

Age and Reproductive Status In pediatric patients, use is generally allowed but requires highly individualized dosing. The drug is assigned to Pregnancy Category C, meaning use is only justified if the potential benefit to the mother outweighs the possible risk to the fetus. Cautious dosage selection is required for the older adult population due to limited specific clinical data.

Interactions with other medicines and products

Official regulatory information for Dihydrotachysterol (DHT) identifies several specific drug-drug, drug-food, and drug-substance interaction patterns. The profile is primarily defined by two regulatory constraints: the risk of additive hypercalcaemic effects (pharmacodynamic) and altered systemic exposure (pharmacokinetic).

Contraindicated and High-Risk Combinations

Co-administration with other Vitamin D Analogs (e.g., Calcitriol, Ergocalciferol) and Calcium Supplements is officially restricted or contraindicated due to the high risk of additive effects leading to toxicity, specifically hypercalcemia. When combined with Cardiac Glycosides (e.g., Digoxin), DHT-induced hypercalcemia may enhance the toxic effects and increase the risk of ventricular arrhythmias, a relationship noted in regulatory warnings.

Exposure-Modifying Interactions

Substances that affect drug metabolism or absorption are documented to alter DHT’s concentration. Anticonvulsants (e.g., Phenytoin, Phenobarbital) may reduce the effectiveness of DHT due to enhanced hepatic metabolism. Conversely, Bile Acid Sequestrants (e.g., Cholestyramine) may impair gastrointestinal absorption and reduce the drug's serum concentration. Thiazide Diuretics are documented to enhance the calcaemic response due to reduced renal calcium excretion. Grapefruit juice is also listed as an agent that may alter plasma concentrations.

How Calciferol (Dihydrotachysterol) Works — Mechanism of Action

Dihydrotachysterol (DHT) is activated in the liver to form a metabolite that functions as an agonist of the nuclear Vitamin D Receptor (VDR). This ligand-receptor complex enters the cell nucleus to modulate gene transcription in target cells. This mechanism operates as a form of genomic signaling modulation, altering the rate of protein synthesis.

VDR agonism influences the calcium and phosphate homeostasis pathway by increasing the synthesis of proteins required for mineral transport. This mechanism enhances the intestinal absorption of calcium and promotes the mobilization of calcium from bone tissue, while simultaneously modulating renal excretion. The combined actions result in an increase in serum (blood) calcium and phosphate concentrations.

By increasing circulating calcium levels, the drug generates an indirect negative feedback signal to the parathyroid glands. The resulting suppression of Parathyroid Hormone (PTH) secretion influences the rate of bone turnover by reducing the PTH-driven signal for bone resorption. This modulates the systemic response of the parathyroid-calcium axis.

Administration Guidelines for Dihydrotachysterol

Dihydrotachysterol (DHT) is administered exclusively via the Oral Route, available in dosage forms including Capsules, Tablets, and an Oral Solution. The medicine is typically taken once daily and may be consumed with or without food.

---

Dosing Schedule and Regimen

Administration follows a two-phase structure for conditions like hypoparathyroidism, requiring the dosage to be highly individualized and constantly monitored:

• Initial (Loading) Phase: Adults typically begin with a high dose, generally 0.8 mg to 2.4 mg daily for a short period (around four days), to achieve initial stability in mineral levels.
• Maintenance Phase: The dose is subsequently reduced to a long-term maintenance range, usually 0.2 mg to 1.0 mg daily, adjusted as needed. The average maintenance dose is 0.6 mg daily.

---

Procedural and Monitoring Rules

Proper use of Dihydrotachysterol is constrained by essential procedural requirements:

1. Concurrent Supplementation: The therapy is used alongside adequate supplemental calcium intake.
2. Dosage Control: Treatment must be guided by regular determinations of blood calcium level (e.g., weekly during the initial phase) to prevent complications. Dose adjustments occur gradually, often at four to eight week intervals.
3. Dose Withholding: The drug must be withheld immediately if tests confirm hypercalcemia, and re-initiated at a lower dose only once serum calcium has returned to the normal range.

In pediatric patients, a similar pattern is followed, starting with a higher initial dose (e.g., 1 mg to 5 mg daily for children) before transitioning to a lower maintenance dose (e.g., 0.5 mg to 1.5 mg daily for children).

Research evidence / Overview of Studies for Calciferol (Dihydrotachysterol)

---

Evidence for Use in Hypoparathyroidism

Dihydrotachysterol (DHT) was studied for its role in managing conditions characterized by low parathyroid hormone (PTH), such as hypoparathyroidism. The research includes older comparative clinical trials and Randomized Controlled Trials (RCTs) where DHT was evaluated in patient groups, including adults and pediatric patients. These studies monitored outcomes related to systemic imbalance, specifically focusing on the achievement and maintenance of stable serum calcium levels over defined time intervals.

Research described patterns observed in the studies related to the regulation of calcium levels. Early trials examined the structure of DHT and how it functions differently from other Vitamin D compounds. However, the evidence quality varies across studies, and many reports rely on older study designs, meaning limited data exist from modern, large-scale, placebo-controlled RCTs. Long-term outcomes, particularly those related to chronic effects outside of basic mineral monitoring, are not fully established.

---

Evidence for Use in Renal Osteodystrophy and Chronic Kidney Disease

Dihydrotachysterol was evaluated in research contexts involving patients with reduced kidney function, particularly those experiencing associated bone disorders. Research scenarios included randomized, double-blind comparative trials where DHT was observed in patients alongside other Vitamin D compounds to see how each agent managed key biomarkers.

These studies examined outcomes such as serum calcium and phosphate levels, and monitored the suppression or maintenance of Parathyroid Hormone (PTH) levels. Research focused on the role of this specific Vitamin D analog structure in mineral balance, which was observed to be activated independently of kidney function. A key limitation noted is that some older studies was associated with observations of changes in Glomerular Filtration Rate (GFR) over the course of treatment in certain patient groups, and comparative evidence is lacking against the newest agents referenced in current treatment guidelines.

---

Evidence Base for Familial Hypophosphatemia

DHT was studied for its application in Familial Hypophosphatemia, an inherited condition characterized by low phosphate levels. The research base relies on older clinical trials and specialized investigations. Studies examined outcomes related to skeletal or functional imbalance, specifically looking at changes in phosphate levels and documenting the status of skeletal abnormalities. Research describes the use of DHT as part of a combination regimen that also includes oral phosphate supplementation.

Key Studies & References

1. Treatment of Hypoparathyroidism: A Randomized Study of Dihydrotachysterol and Calcitriol

Common questions about Calciferol (Dihydrotachysterol) (FAQ)

Q: What is the main difference between Dihydrotachysterol and regular Vitamin D?

Dihydrotachysterol is classified as a Vitamin D analog. Official product information states that its distinguishing feature is its structure, which allows it to be primarily activated by the liver. This means it bypasses the final activation step that regular Vitamin D requires in the kidneys, making it a specialized option for mineral regulation.

Q: Can people with liver problems use Dihydrotachysterol?

The drug relies on the liver for conversion into its active form. Regulatory information suggests that when liver impairment is present, careful management is required. The determination of use in this population is based on a healthcare provider's assessment of individual circumstances.

Q: Can food affect how Dihydrotachysterol works?

Yes, regulatory information indicates that certain foods may affect the medicine. Consumption of grapefruit or grapefruit juice is documented to potentially alter the levels of the drug in the bloodstream. Additionally, patients are usually advised to adjust their dietary intake of foods containing calcium and phosphate.

Q: Can Dihydrotachysterol affect bone density?

The drug is known to mobilize calcium from bone tissue. In cases where the drug leads to severe or prolonged high calcium levels (hypercalcemia), official documents mention potential bone demineralization in adults as a serious adverse effect.

Q: What specific conditions does Dihydrotachysterol treat?

According to official regulatory documents, this medicine is used to manage specific conditions associated with mineral imbalances and low calcium. Primary uses include the treatment of hypoparathyroidism, rickets, and renal osteodystrophy.

Q: Are there any long-term effects associated with taking Dihydrotachysterol?

Long-term concerns are primarily related to the persistent occurrence of abnormally high calcium levels, known as hypercalcemia. Serious adverse reactions documented in regulatory documents linked to chronic hypercalcemia include soft tissue calcification (metastatic calcification) and potential renal failure.

Q: Is it normal to feel nauseous when starting Dihydrotachysterol?

Nausea and vomiting are listed among the documented gastrointestinal side effects. It is important to know that these symptoms may also be a sign of abnormally elevated calcium levels (hypercalcemia), which requires close monitoring by a healthcare professional.

Q: Can Dihydrotachysterol cause an upset stomach?

Official adverse reaction listings include several gastrointestinal symptoms. These may be described by patients as an upset stomach and include nausea, vomiting, abdominal pain, and constipation.

Q: What should I watch out for while taking Dihydrotachysterol?

Regulatory warnings stress the need for vigilance regarding symptoms of high blood calcium, or hypercalcemia. These symptoms may include increased urination, excessive thirst, persistent headache, nausea, and vomiting. It is important that any of these signs are communicated to a healthcare professional.

Q: Should I avoid any specific vitamins or supplements while on Dihydrotachysterol?

Regulatory labels advise against combining Dihydrotachysterol with other Vitamin D analogs. Furthermore, use with supplemental calcium is either restricted or contraindicated due to the risk of excessively high calcium levels.

Q: Does Dihydrotachysterol interact with anticonvulsants?

Yes, regulatory documents note a specific drug interaction with certain anticonvulsant medicines. This interaction may reduce the effectiveness of Dihydrotachysterol due to enhanced metabolism in the liver.

Q: Does Dihydrotachysterol have potential interactions with common herbal supplements?

While specific herbal products may not be listed, official product information generally advises patients to inform their healthcare professional about all medicines they are taking, including vitamins and herbal products. This is noted as a general safety practice.

Q: Is Dihydrotachysterol safe for people who have had stomach surgery?

Since this drug works by enhancing the intestinal absorption of calcium, conditions or procedures that impact the body's ability to absorb nutrients, such as certain types of stomach surgery, may potentially affect the drug's intended function or effectiveness.

Q: How does the evidence compare Dihydrotachysterol to other treatments for related conditions?

Studies have been conducted that compare Dihydrotachysterol with other Vitamin D compounds and related treatments used to manage mineral imbalances. Official regulatory summaries indicate that these comparisons often focus on the ability of the drug to manage key biomarkers like calcium and phosphate levels.

Q: Why do some people need Dihydrotachysterol instead of Vitamin D supplements?

This medication is a specialized Vitamin D analog that is notably activated by the liver and does not require the final kidney activation step. This mechanism makes it a suitable alternative for patients who have compromised kidney function and need predictable mineral regulation.

Q: Do I need to change my diet while taking Dihydrotachysterol?

Official regulatory labels indicate that certain dietary adjustments may be necessary during treatment. This involves the required careful control of dietary intake of foods containing calcium, phosphate, and Vitamin D. Grapefruit should also be avoided.

Q: Can Dihydrotachysterol affect my mood or sleep?

Adverse reaction listings include somnolence (drowsiness) and vertigo (a form of dizziness). The effects described may include reduced wakefulness or balance.

Q: How long does Dihydrotachysterol stay in your system after stopping it?

Official product information notes that the effects of the drug, particularly the high calcium levels seen in cases of overdosage or toxicity, may persist for a significant period. These effects may continue for up to one month after discontinuing treatment.

Q: Can Dihydrotachysterol cause skin sensitivity to the sun?

Regulatory documents do not list sun sensitivity as a common side effect. However, they note that light sensitivity (photophobia) is a potential symptom associated with toxic effects stemming from highly elevated calcium levels (hypercalcemia).

Q: Are there any specific lifestyle restrictions when taking Dihydrotachysterol?

Specific lifestyle guidance in official documents focuses primarily on dietary restrictions, requiring careful control of intake of calcium, phosphate, and Vitamin D-containing foods and avoidance of grapefruit. There are no other major lifestyle restrictions listed in regulatory warnings.

Q: Is Dihydrotachysterol effective for Vitamin D deficiency?

Regulatory documents list Vitamin D deficiency as an indication for the use of this drug. However, its primary role is generally in managing conditions related to mineral imbalance, particularly hypoparathyroidism.

Q: Can Dihydrotachysterol cause dizziness?

Official side effect listings include vertigo, which is a medical term for a sensation of dizziness. This is listed among potential nervous system disorders.

Official Storage and Disposal Requirements

Official regulatory guidelines for Dihydrotachysterol focus on environmental protection, stability, and controlled access due to its potency.

Requirement Area	Stated Conditions
Storage Environment	Store the container tightly closed in a cool, dry, and well-ventilated area.
Protection & Safety	The product must be stored locked up (P405) and protected from incompatible materials. Avoid inhalation of dusts and contact with skin or eyes during handling.
Disposal Instructions	Follow any specific labeled instructions, utilize a community drug take-back program, or mix with undesirable material and seal for household trash.
Environmental Rule	Avoid release to the environment (P273); do not dispose of the substance in drains or sewer systems. Final disposal must be via an approved waste disposal plant or licensed chemical destruction facility.